Heparin-induced Thrombocytopenia Market Players:
- Endo International plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- PlateletBio
- AUROMEDICS PHARMA LLC
- Fresenius Kabi USA
- Pfizer Inc
- Caplin Steriles Ltd
- Hikma Pharmaceuticals PLC
- Teva Pharmaceuticals Industries Limited
- NOVARTIS AG
- Eagle Pharmaceutical Inc
- WEST WARD INC
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of heparin-induced thrombocytopenia is assessed at USD 10.92 billion.
The global heparin-induced thrombocytopenia market size was valued at over USD 10.42 billion in 2025 and is expected to register a CAGR of over 5.3%, exceeding USD 17.46 billion revenue by 2035.
North America heparin-induced thrombocytopenia market is growing steadily with a 33% share by 2035, driven by increasing dialysis use and introduction of novel therapies.
Key players in the market include Pfizer Inc, Caplin Steriles Ltd, Hikma Pharmaceuticals PLC, Teva Pharmaceuticals Industries Limited, NOVARTIS AG, Eagle Pharmaceutical Inc., WEST WARD INC.
